Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
AG
AgomAb Therapeutics NV American Depositary Shares
AGMB
Mkt Cap
$411.0M
Volume
74.50K
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
AG
AGMB
AG
AgomAb Therapeutics NV American Depositary Shares
AGMB
News
·
Agomab Announces Results of Annual General Meeting
Mkt Cap
$407.8M
Volume
74.50K
Next Earnings
N/A
Chart
Earnings
News
About
Insider
Filings
Agomab Announces Results of Annual General Meeting
Agomab Therapeutics NV held its Annual General Meeting on May 26, 2026, with all agenda items approved including financial statements for 2025 and board member reappointments. The company reported full year 2025 financial results and confirmed its 2026 outlook.
GlobeNewswire Inc. · May 27, 2026
Agomab Reports Full Year 2025 Financial Results and Confirms 2026 Outlook
Agomab Therapeutics reported €116.5 million in cash at year-end 2025 and raised $208 million in gross IPO proceeds in February 2026, extending cash runway into H1 2029. The company achieved positive Phase 2a results for ontunisertib in fibrostenosing Crohn's disease and positive Phase 1 results for AGMB-447 in healthy participants. Agomab is on track to initiate Phase 2b studies for both lead candidates in H2 2026, with topline data from extension and IPF cohort studies expected in the same period.
GlobeNewswire Inc. · Apr 23, 2026
Agomab Receives U.S. Patent for AGMB-447, its Inhaled Lung-restricted Small Molecule Inhibitor of ALK5 in Development for the Treatment of Idiopathic Pulmonary Fibrosis
Agomab Therapeutics NV announced that the USPTO granted U.S. Patent No. 12,577,230 for AGMB-447, an investigational inhaled lung-restricted small molecule inhibitor of ALK5 for treating Idiopathic Pulmonary Fibrosis. The patent provides IP protection through at least 2041. The company is currently conducting a Phase 1b study and expects to report results from the IPF patient cohort later in 2026.
GlobeNewswire Inc. · Mar 26, 2026
Agomab Announces Closing of Initial Public Offering
Agomab Therapeutics NV (NASDAQ: AGMB), a clinical-stage biopharmaceutical company focused on developing disease-modifying therapies for immunology and inflammatory diseases, announced the successful closing of its IPO on February 9, 2026. The company offered 12.5 million American Depositary Shares at $16.00 per share, raising approximately $200 million in gross proceeds. Trading began on the Nasdaq Global Select Market on February 6, 2026.
Benzinga · Feb 9, 2026
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
AG
AGMB
AgomAb Therapeutics NV American Depositary Shares
Buy
Sell
Market
Limit
Soon
AGMB
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any AGMB yet.
Related Tickers
Earnings